Literature DB >> 24741085

Determinants of Moloney murine leukemia virus Gag-Pol and genomic RNA proportions.

Silas F Johnson1, John T Collins1, Victoria M D'Souza2, Alice Telesnitsky3.   

Abstract

UNLABELLED: The Moloney murine leukemia virus (MoMLV) ribonucleoprotein complex is composed of an approximately 20:1 mixture of Gag and Gag-Pol polyproteins plus a single genomic RNA (gRNA) dimer. The mechanisms that regulate these proportions are unknown. Here, we examined whether virion proportions of Gag, Gag-Pol, and gRNA were determined by sampling (that is, if they reflected expression ratios or intracellular concentrations) or more specific recruitment. To this end, MoMLV Gag, Gag-Pol, and gRNA were expressed separately or together in various ratios. Varying the expression ratios of Gag and Gag-Pol revealed that Gag-Pol incorporation was stochastic and that the conserved 20:1 Gag/Gag-Pol ratio coincided with maximal particle production. When skewed expression ratios resulted in excess Gag-Pol, the released virions maintained the intracellular Gag/Gag-Pol ratios and the infectivity per virion was largely maintained, but virion production decreased sharply with high levels of Gag-Pol. The determinants of gRNA proportions were addressed by manipulating the amounts and contexts of functional nucleocapsid (NC) and the ratios of Gag to gRNA. The results showed that the NC domain of either Gag or Gag-Pol could provide gRNA packaging functions equally well. Unlike Gag-Pol, gRNA incorporation was saturable. An upper limit of gRNA incorporation was observed, and particle production was not disrupted by excess gRNA expression. These results indicate that the determinants of Gag/Gag-Pol proportions differ from those for Gag/gRNA. On the basis of the assumption that MoMLV evolved to produce virion components in optimal proportions, these data provide a means of estimating the proportion of unspliced MoMLV RNA that serves as genomic RNA. IMPORTANCE: Viruses assemble their progeny from within the cells that they parasitize, where they must sort through a rich milieu of host proteins and nucleic acids to gather together their own building blocks, which are also proteins and nucleic acids. The research described here addresses whether or not the proportions of viral proteins and nucleic acids that are brought together to form a retroviral particle are determined by random sampling from the cell-and thus dictated by the components' availabilities within the cell-or if the amounts of each molecule are specified by the virus replication process. The results indicated that protein components of the murine retrovirus studied here are recruited by chance but that a specific counting mechanism defines the amount of nucleic acid incorporated into each progeny virion.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24741085      PMCID: PMC4054431          DOI: 10.1128/JVI.03513-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Identification of residues of the Moloney murine leukemia virus nucleocapsid critical for viral DNA synthesis in vivo.

Authors:  J Gonsky; E Bacharach; S P Goff
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Mutational analysis of stem-loops in the RNA packaging signal of the Moloney murine leukemia virus.

Authors:  J Fisher; S P Goff
Journal:  Virology       Date:  1998-04-25       Impact factor: 3.616

3.  Second-site changes affect viability of amphotropic/ecotropic chimeric enveloped murine leukemia viruses.

Authors:  L O'Reilly; M J Roth
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 4.  Retroviral RNA packaging: a review.

Authors:  A Rein
Journal:  Arch Virol Suppl       Date:  1994

5.  Role of murine leukemia virus nucleocapsid protein in virus assembly.

Authors:  Delphine Muriaux; Sylvain Costes; Kunio Nagashima; Jane Mirro; Ed Cho; Stephen Lockett; Alan Rein
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Packaging of host mY RNAs by murine leukemia virus may occur early in Y RNA biogenesis.

Authors:  Eric L Garcia; Adewunmi Onafuwa-Nuga; Soyeong Sim; Steven R King; Sandra L Wolin; Alice Telesnitsky
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

7.  Synthesis of murine leukemia virus proteins associated with virions assembled in actinomycin D-treated cells: evidence for persistence of viral messenger RNA.

Authors:  J G Levin; M J Rosenak
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

8.  Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon.

Authors:  Y Yoshinaka; I Katoh; T D Copeland; S Oroszlan
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  Murine leukemia viruses: objects and organisms.

Authors:  Alan Rein
Journal:  Adv Virol       Date:  2011-11-15

Review 10.  Translational suppression in retroviral gene expression.

Authors:  D L Hatfield; J G Levin; A Rein; S Oroszlan
Journal:  Adv Virus Res       Date:  1992       Impact factor: 9.937

View more
  3 in total

1.  On genome annotation of Brucellaphage Gadvasu (BpG): discovery of ORFans for integrated systems biology approaches.

Authors:  Deepti Chachra; Pushpinder Kaur; Prasad Siddavatam; Prashanth Suravajhala; Hari Mohan Saxena
Journal:  Syst Synth Biol       Date:  2015-11-21

2.  Stability of HIV Frameshift Site RNA Correlates with Frameshift Efficiency and Decreased Virus Infectivity.

Authors:  Pablo Garcia-Miranda; Jordan T Becker; Bayleigh E Benner; Alexander Blume; Nathan M Sherer; Samuel E Butcher
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

3.  Perturbation of Human T-Cell Leukemia Virus Type 1 Particle Morphology by Differential Gag Co-Packaging.

Authors:  José O Maldonado; Isaac Angert; Sheng Cao; Serkan Berk; Wei Zhang; Joachim D Mueller; Louis M Mansky
Journal:  Viruses       Date:  2017-07-19       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.